欧洲静脉免疫球蛋白市场预测至 2028 年 - COVID-19 影响和区域分析 - 按类型（胭脂红、花青素、焦糖、姜黄素、胭脂红、类胡萝卜素、叶绿素等）、形式（液体、凝胶和粉末）、和应用（烘焙和糖果、乳制品和冷冻甜点、饮料、酱汁、调料和调味品、RTC 和 RTE 产品、肉类、家禽和海鲜等）
No. of Pages: 186 | Report Code: BMIRE00027587 | Category: Life Sciences
No. of Pages: 186 | Report Code: BMIRE00027587 | Category: Life Sciences
静脉注射免疫球蛋白（IVIG）用于治疗患有原发性和继发性免疫缺陷以及自身免疫性疾病的患者。 IVIG 是治疗大多数原发性免疫缺陷 (PID) 的标准疗法。罕见的遗传疾病可能是慢性的、衰弱的并且治疗费用昂贵。免疫性血小板减少症（ITP）是一种自身免疫性出血性疾病，其特征是血小板水平异常低——这种情况称为血小板减少症。根据罕见疾病组织的数据，该地区每年记录约 200,000 例 ITP 病例。因此，免疫缺陷疾病的日益流行推动了静脉注射免疫球蛋白市场的发展。
欧洲是第二大市场，原因包括老年人口增加、免疫缺陷和自身免疫性疾病患病率增加以及该地区对新疗法开发的高需求等因素。此外，用于研究和开发的资金不断增加。未来几年的发展活动可能会为本地区带来更多机会。德国的制药业在中小企业中占据第四大地位。据国际贸易管理局（ITA）统计，2019年德国医药市场规模达625亿美元。就制造和供应而言，未来几年该国可能仍然是全球制药业最具吸引力的目的地之一。该行业的增长是由研发投资的增加和专利申请的增加推动的。
开发 IVIg 疗法的本地市场参与者可能有利于市场增长。例如，总部位于德国的 Biotest AG 正在开发用于从人血浆静脉注射的多价免疫球蛋白制剂，以治疗免疫缺陷和自身免疫性疾病。
欧洲静脉注射免疫球蛋白市场按类型、应用、分销渠道、最终用户和国家细分。根据类型，市场分为 IgG、IgM、IgA、IgE 和 IgD。 2022 年 IgG 细分市场占据最大市场份额。
ADMA Biologics, Inc.；生物制品实验室有限公司； CSL贝林（CSL有限公司）； Grifols，SA； Kedrion SpA； Octapharma AG；辉瑞公司； Prothya Biosolutions BV；上海莱士;和武田药品有限公司是该地区静脉注射免疫球蛋白市场的领先公司之一。
Strategic insights for Europe Intravenous Immunoglobulin involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 3,495.39 Million |
| Market Size by 2028 | US$ 5,363.10 Million |
| Global CAGR (2022 - 2028) | 7.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Intravenous Immunoglobulin refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Intravenous Immunoglobulin Market is valued at US$ 3,495.39 Million in 2022, it is projected to reach US$ 5,363.10 Million by 2028.
As per our report Europe Intravenous Immunoglobulin Market, the market size is valued at US$ 3,495.39 Million in 2022, projecting it to reach US$ 5,363.10 Million by 2028. This translates to a CAGR of approximately 7.4% during the forecast period.
The Europe Intravenous Immunoglobulin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Intravenous Immunoglobulin Market report:
The Europe Intravenous Immunoglobulin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Intravenous Immunoglobulin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Intravenous Immunoglobulin Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Intravenous Immunoglobulin Market
